hotspot -WSS

hotspot

author：hotspot 2025-09-29 23:28:15 - browse：18

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Stigma and the return of syphilis

WSS

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Akili, maker of video game for ADHD, to be acquired for 34 million

Startling documents reveal new facets of Sacklers' opioid empire

Prosthetic arm enables patients to feel the objects they grip

Childbirth

David Sabatini, ex

focus

hotspot

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Health insurers say they are turning to AI to cut costs, improve care

Malaria cases in Florida and Texas: Here’s what you need to know

Latest bird flu infection made farmworker sicker than earlier cases

Heart attack and stroke risk calculators need revising

Health insurers say they are turning to AI to cut costs, improve care

Heart attack and stroke risk calculators need revising

Focused ultrasound for uterine fibroids: an uphill battle

Cancer drug shortages should be causing more outrage

David Sabatini, ex

explore

Antibiotic resistance nearly killed me, so I'm raising awareness of it

First Opinion Podcast: What happens when kids become caregivers?

Health insurers say they are turning to AI to cut costs, improve care

Average age of first period drops to 11.9 years, study shows

First Opinion Podcast: What happens when kids become caregivers?

Do more moles mean more problems? Not so, says new study

hotspot

focus

leisure time

explore